1. |
Lyu K, Tian Y, Shang Y, et al. Causal knowledge graph construction and evaluation for clinical decision support of diabetic nephropathy. J Biomed Inform, 2023, 139: 104298.
|
2. |
Vitale M, Masulli M, Calabrese I, et al. Impact of a mediterranean dietary pattern and its components on cardiovascular risk factors, glucose control, and body weight in people with type 2 diabetes: A real-life study. Nutrients, 2018, 10(8): 1067.
|
3. |
Alicic RZ, Johnson EJ, Tuttle KR. SGLT2 inhibition for the prevention and treatment of diabetic kidney disease: a review. Am J Kidney Dis, 2018, 72(2): 267-277.
|
4. |
Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes-5-year outcomes. N Engl J Med, 2017, 376(7): 641-651.
|
5. |
Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2018, 61(12): 2461-2498.
|
6. |
Sandoval DA, Patti ME. Glucose metabolism after bariatric surgery: implications for T2DM remission and hypoglycaemia. Nat Rev Endocrinol, 2023, 19(3): 164-176.
|
7. |
O’Brien R, Johnson E, Haneuse S, et al. Microvascular outcomes in patients with diabetes after bariatric surgery versus usual care: A matched cohort study. Ann Intern Med, 2018, 169(5): 300-310.
|
8. |
Holcomb CN, Goss LE, Almehmi A, et al. Bariatric surgery is associated with renal function improvement. Surg Endosc, 2018, 32(1): 276-281.
|
9. |
Frangogiannis N. Transforming growth factor-β in tissue fibrosis. J Exp Med, 2020, 217(3): e20190103.
|
10. |
Christou GA, Katsiki N, Blundell J, et al. Semaglutide as a promising antiobesity drug. Obes Rev, 2019, 20(6): 805-815.
|
11. |
Chen G, Zhang GX, Peng BQ, et al. Roux-en-Y gastric bypass versus sleeve gastrectomy plus procedures for treatment of morbid obesity: systematic review and meta-analysis. Obes Surg, 2021, 31(7): 3303-3311.
|
12. |
de Moura DTH, Barrichello S, de Moura EGH, et al. Endoscopic sleeve gastroplasty in the management of weight regain after sleeve gastrectomy. Endoscopy, 2020, 52(3): 202-210.
|
13. |
Santoro S, Castro LC, Velhote MC, et al. Sleeve gastrectomy with transit bipartition: a potent intervention for metabolic syndrome and obesity. Ann Surg, 2012, 256(1): 104-110.
|
14. |
Bagai S, Bansal B, Malik V, et al. A friend or a foe? Bariatric surgery in chronic kidney disease: a case report. Case Rep Nephrol Dial, 2022, 12(3): 207-211.
|
15. |
Cohen RV, Pereira TV, Aboud CM, et al. Gastric bypass versus best medical treatment for diabetic kidney disease: 5 years follow up of a single-centre open label randomised controlled trial. EClinicalMedicine, 2022, 53: 101725.
|
16. |
Samsu N. Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment. Biomed Res Int, 2021, 2021: 1497449.
|
17. |
Upala S, Wijarnpreecha K, Congrete S, et al. Bariatric surgery reduces urinary albumin excretion in diabetic nephropathy: a systematic review and meta-analysis. Surg Obes Relat Dis, 2016, 12(5): 1037-1044.
|
18. |
Khan TM, Nawaz FK, Karim MS, et al. Incidence of microalbuminuria and factors affecting it in patients with type 2 diabetes mellitus. Cureus, 2022, 14(7): e27294.
|
19. |
Wang Y, Zhou Q, Zhang L, et al. Urine haptoglobin/creatinine ratio correlates with tubular injury biomarkers and severity of albuminuria in type 2 diabetes patients. Horm Metab Res, 2019, 51(9): 595-601.
|
20. |
Ding H, Zhang Y, Ma X, et al. Bariatric surgery for diabetic comorbidities: A focus on hepatic, cardiac and renal fibrosis. Front Pharmacol, 2022, 13: 1016635.
|
21. |
Luo J, Hodge A, Hendryx M, et al. Age of obesity onset, cumulative obesity exposure over early adulthood and risk of type 2 diabetes. Diabetologia, 2020, 63(3): 519-527.
|
22. |
Scheurlen KM, Probst P, Kopf S, et al. Metabolic surgery improves renal injury independent of weight loss: a meta-analysis. Surg Obes Relat Dis, 2019, 15(6): 1006-1020.
|
23. |
Köhler H, Bollenbach IA, Gruner-Labitzke K, et al. Improvement of work ability after weight loss surgery: results of a longitudinal study of patients suffering from extreme obesity before and 4 years after bariatric surgery. Obes Surg, 2023, 33(5): 1347-1355.
|
24. |
D’Alessio D. Is GLP-1 a hormone: whether and when?. J Diabetes Investig, 2016, 7 Suppl 1(Suppl 1): 50-55.
|
25. |
Greco EV, Russo G, Giandalia A, et al. GLP-1 receptor agonists and kidney protection. Medicina (Kaunas), 2019, 55(6): 233.
|
26. |
Najafi S, Bahrami M, Butler AE, et al. The effect of glucagon-like peptide-1 receptor agonists on serum uric acid concentration: A systematic review and meta-analysis. Br J Clin Pharmacol, 2022, 88(8): 3627-3637.
|
27. |
Zatterale F, Longo M, Naderi J, et al. Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes. Front Physiol, 2020, 10: 1607.
|
28. |
Saad R, Habli D, El Sabbagh R, et al. Bone health following bariatric surgery: an update. J Clin Densitom, 2020, 23(2): 165-181.
|
29. |
Assalia A, Gagner M, Nedelcu M, et al. Gastroesophageal Reflux and Laparoscopic Sleeve Gastrectomy: Results of the First International Consensus Conference. Obes Surg, 2020 , 30(10): 3695-3705.
|
30. |
Gomes-Rocha SR, Costa-Pinho AM, Pais-Neto CC, et al. Roux-en-Y gastric bypass vs sleeve gastrectomy in super obesity: a systematic review and meta-analysis. Obes Surg, 2022, 32(1): 170-185.
|
31. |
Conner J, Nottingham JM. Biliopancreatic diversion with duodenal switch. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: James Nottingham declares no relevant financial relationships with ineligible companies. 2023: 21(4): 136-141.
|
32. |
Lind RP, Ghanem M, Teixeira AF, et al. Single- versus double-anastomosis duodenal switch: outcomes stratified by preoperative BMI. Obes Surg, 2022, 32(12): 3869-3878.
|
33. |
Topart P, Becouarn G, Finel JB. Comparison of 2-year results of Roux-en-Y gastric bypass and transit bipartition with sleeve gastrectomy for superobesity. Obes Surg, 2020, 30(9): 3402-3407.
|